Frozen in time: rethinking cryopreservation as a core process parameter in cell and gene therapy
Cell and Gene Therapy Insights · 09.07.2026 · 12 (5) · 589–596
DOI: 10.18609/cgti.2026.072 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell and Gene Therapy Insights, online erschienen am 09.07.2026. Verfasst von Jason Acker. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
“These are complex scientific and technical problems that require and benefit from all the discovery work that we do in the cryopreservation and cryoinjury space.”Wil Rich, Editor, Cell & Gene Therapy Insights , speaks with Jason Acker, Professor, University of Alberta, and Senior Scientist, Canadian Blood Services, about the evolution of biopreservation science, the persistent gap between cryobiology research and cell and gene therapy (CGT) manufacturing practice, and the emerging molecular and chemical strategies that could transform how cell therapies are stabilized, stored, and delivered to patients.
Zitieren
APA
Acker, J. (2026). Frozen in time: rethinking cryopreservation as a core process parameter in cell and gene therapy. Cell and Gene Therapy Insights, 12(5), 589–596. https://doi.org/10.18609/cgti.2026.072
Vancouver
Acker J. Frozen in time: rethinking cryopreservation as a core process parameter in cell and gene therapy. Cell and Gene Therapy Insights. 2026;12(5):589–596. doi:10.18609/cgti.2026.072
BibTeX
@article{Acker2026,
author = {Acker, Jason},
title = {Frozen in time: rethinking cryopreservation as a core process parameter in cell and gene therapy},
journal = {Cell and Gene Therapy Insights},
year = {2026},
volume = {12},
number = {5},
pages = {589–596},
doi = {10.18609/cgti.2026.072}
}
EUVIMED